×

Will the Mylan case force rule changes?

12:05 PM ET Thu, 25 Aug 2016

The "FMHR" panel and David Maris, specialty pharmaceutical analyst at Wells Fargo Securities, discuss the latest on the EpiPen pricing outrage.